ENXTPA:ALCLS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Cellectis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALCLS is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ALCLS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

8.4%

ALCLS

3.0%

FR Biotechs

1.1%

FR Market


1 Year Return

54.0%

ALCLS

35.5%

FR Biotechs

-2.6%

FR Market

Return vs Industry: ALCLS exceeded the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: ALCLS exceeded the French Market which returned -3% over the past year.


Shareholder returns

ALCLSIndustryMarket
7 Day8.4%3.0%1.1%
30 Day31.5%12.0%15.2%
90 Day26.4%22.3%11.6%
1 Year54.0%54.0%35.5%35.5%-0.6%-2.6%
3 Year-4.5%-4.5%-31.8%-31.9%16.8%7.1%
5 Year-36.6%-36.6%-63.5%-63.7%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is Cellectis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cellectis undervalued compared to its fair value and its price relative to the market?

3.39x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALCLS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALCLS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALCLS is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: ALCLS is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALCLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALCLS is overvalued based on its PB Ratio (3.4x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Cellectis forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

3.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALCLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALCLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALCLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALCLS's revenue (39.1% per year) is forecast to grow faster than the French market (7.3% per year).

High Growth Revenue: ALCLS's revenue (39.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALCLS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cellectis performed over the past 5 years?

-12.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALCLS is currently unprofitable.

Growing Profit Margin: ALCLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALCLS is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.

Accelerating Growth: Unable to compare ALCLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALCLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: ALCLS has a negative Return on Equity (-28.61%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cellectis's financial position?


Financial Position Analysis

Short Term Liabilities: ALCLS's short term assets ($345.7M) exceed its short term liabilities ($56.6M).

Long Term Liabilities: ALCLS's short term assets ($345.7M) exceed its long term liabilities ($102.1M).


Debt to Equity History and Analysis

Debt Level: ALCLS is debt free.

Reducing Debt: ALCLS has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALCLS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ALCLS has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 41.2% each year.


Next Steps

Dividend

What is Cellectis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALCLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALCLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALCLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALCLS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALCLS's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

André Choulika (55 yo)

21.83yrs

Tenure

US$1,001,637

Compensation

Dr. André Choulika, Ph.D. is the Founder of Cellectis SA and has been its Chief Executive Officer since 1999 and served as its Chairman until November 5, 2020. Dr. Choulika is a pioneer in the analysis and...


CEO Compensation Analysis

Compensation vs Market: André's total compensation ($USD1.00M) is above average for companies of similar size in the French market ($USD746.22K).

Compensation vs Earnings: André's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
André Choulika
Co-Founder21.83yrsUS$1.00m2.34%
$ 19.4m
David J. Sourdive
Co-Founder20.83yrsUS$452.66k0.66%
$ 5.4m
Eric Dutang
Chief Financial Officer4.75yrsno datano data
Jean Epinat
Chief Technological Officerno datano datano data
Stephan Reynier
Chief Regulatory & Compliance Officerno datano data0.036%
$ 294.3k
Marie-Bleuenn Terrier
General Counsel7.83yrsno data0.061%
$ 505.7k
Jennifer Moore
Senior Vice President of Public Relationsno datano datano data
Kyung Nam-Wortman
Executive VP & Chief Human Resources Officerno datano datano data
Philippe Duchateau
Chief Scientific Officer8.83yrsno data0.091%
$ 751.8k
Simon Harnest
Senior Vice President of Corporate Strategy & Financeno datano datano data
Stéphane Dépil
Senior VP of Research & Development and Chief Medical Officer2.92yrsno datano data
Jon Voss
Executive Vice President of Global Quality1.33yrsno datano data

6.3yrs

Average Tenure

52yo

Average Age

Experienced Management: ALCLS's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
André Choulika
Co-Founder21.83yrsUS$1.00m2.34%
$ 19.4m
David J. Sourdive
Co-Founder20.83yrsUS$452.66k0.66%
$ 5.4m
Pascale Augé
Advisor & Non-Voting Directorno datano datano data
Jean-Pierre Garnier
Non-Executive Chairmanno datano datano data
Alain Godard
Independent Director13.08yrsUS$58.58k0.051%
$ 419.4k
Laurent Arthaud
Independent Director9.08yrsno datano data
Yves Ribeill
Chairman of the Board0.33yrno datano data
Pierre Bastid
Independent Director9.08yrsUS$62.70k0.13%
$ 1.1m
Annick Schwebig
Independent Director9.08yrsUS$55.98k0.0046%
$ 37.8k
Alain Fischer
Member of Medical Advisory Boardno datano datano data
Véronique Leblond
Member of Medical Advisory Boardno datano datano data
David Linch
Member of Medical Advisory Boardno datano datano data

9.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ALCLS's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cellectis S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cellectis S.A.
  • Ticker: ALCLS
  • Exchange: ENXTPA
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €826.839m
  • Shares outstanding: 42.49m
  • Website: https://www.cellectis.com

Number of Employees


Location

  • Cellectis S.A.
  • 8, rue de la Croix Jarry
  • Paris
  • Ile-de-France
  • 75013
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCLSENXTPA (Euronext Paris)YesOrdinary SharesFREURFeb 2007
ZVADB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2007
CMVL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2007
0WA2LSE (London Stock Exchange)YesOrdinary SharesGBEURFeb 2007
CLLSNasdaqGM (Nasdaq Global Market)SPON ADSUSUSDMar 2015
ZVAADB (Deutsche Boerse AG)SPON ADSDEEURMar 2015

Biography

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It op...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 20:18
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.